POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY

Abstract

BackgroundGiven the chronic, long-term nature of psoriatic arthritis (PsA), sustaining high levels of disease control with treatment is important. Assessing the maintenance of response in patients (pts) that achieve treatment...